Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

被引：0

作者：

Farber, Harrison W. ^{[1
]}

Germack, Hayley D. ^{[2
]}

Croteau, Nicole S. ^{[3
]}

Simeone, Jason C. ^{[3
]}

Tang, Fei ^{[3
]}

Paoli, Carly J. ^{[2
]}

Doad, Gurinderpal ^{[4
]}

Panjabi, Sumeet ^{[2
]}

De Marco, Teresa ^{[5
]}

机构：

[1] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA

[2] Janssen Sci Affairs LLC, Titusville, NJ USA

[3] Cytel, Real World Evidence, Waltham, MA USA

[4] Actelion Pharmaceut, Titusville, NJ USA

[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA

来源：

PULMONARY CIRCULATION | 2024年 / 14卷 / 02期

关键词：

pulmonary arterial hypertension; risk factors; treatment;

D O I：

10.1002/pul2.12326

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.

引用

页数：5

共 50 条

[31] Factors associated with hypertension awareness in the United States adult population
Hyre, AD
Muntner, P
DeSalvo, KB
Whelton, PK
He, J
CIRCULATION, 2005, 111 (14) : E234 - E234
[32] THE DISCONTINUATION SYNDROME IN CLOFELIN TREATMENT OF ARTERIAL-HYPERTENSION
ZAMOTAEV, IP
ABRAMOVA, VG
STANKOVSKAYA, IM
KLINICHESKAYA MEDITSINA, 1983, 61 (03): : 49 - 51
[33] Factors associated with daily physical activity in patients with Pulmonary arterial hypertension
Lima, Layse
Mendes, Felipe
Moreira, Marcos
Oliveira, Daniela
Pereira, Monica
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[34] Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)
Jiang, Yuxuan
Turk, Matthew A.
Pope, Janet E.
AUTOIMMUNITY REVIEWS, 2020, 19 (09)
[35] Risk stratification and prognostic factors in pulmonary arterial Hypertension and pulmonary arterial Hypertension with comorbidities
Xanthouli, P.
Koegler, M.
Benjamin, N.
Fischer, L.
Egenlauf, B.
Eichstaedt, C.
Harutyunova, S.
Marra, A. M.
Nagel, C.
Theobald, V
Gruenig, E.
PNEUMOLOGIE, 2020, 74 : S123 - S123
[36] Risk factors for pulmonary arterial hypertension
Humbert, M
Nunes, H
Sitbon, O
Parent, F
Hervé, P
Simonneau, G
CLINICS IN CHEST MEDICINE, 2001, 22 (03) : 459 - +
[37] The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
Ogbomo, Adesuwa
Tsang, Yuen
Mallampati, Rajesh
Panjabi, Sumeet
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (06): : 608 - 616
[38] Reunited and united against pulmonary arterial hypertension
Robert, Philippe
INSUFICIENCIA CARDIACA, 2013, 8 (04) : 202 - 202
[39] Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases
Boueiz, Adel
Hassoun, Paul M.
ANNALS OF THORACIC MEDICINE, 2014, 9 (05) : 26 - 37
[40] Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease
Lopes, Antonio
Alnajashi, Khalid
ANNALS OF THORACIC MEDICINE, 2014, 9 (05) : 21 - 25

← 1 2 3 4 5 →